(The Epoch Times)—Ivermectin was found to be highly toxic against certain mosquito types and can be used as an effective tool in malaria management, according to a peer-reviewed study published in Nature on Oct. 31.
Ivermectin became controversial during the COVID-19 pandemic when many health officials denounced its usage, while others praised the drug for its efficacy. Since its discovery in the late 1970s, it has been used worldwide for treating infections caused by gastrointestinal roundworms, lungworms, and other parasites.
Many regions in Africa have been using ivermectin for malaria management, and in places where there was mass drug administration, it has been observed to “significantly reduce” the mosquito population, the study said.
Researchers based in India looked at the potential of ivermectin as a “contact-toxin” for malaria transmitters and parasites. Contact toxins are toxins that are absorbed through direct skin contact.
The study exposed lab-reared female An. culicifacies and An. stephensi mosquitoes to varying concentrations of ivermectin. Both mosquito types are the major malaria vectors in India.
When ivermectin was administered to the mosquitoes, researchers found that there was “significantly high mortality” depending on the drug concentration and the method of administration.
Mortality rate climbed as dosage was raised, with the highest ivermectin concentration resulting in a 100 percent mortality rate.
“This study also pin-pointed the fact that ivermectin when applied to treated surfaces exhibited faster killing effect among mosquitoes in contrast to when ingested through blood meal from treated individuals,” it said.
“When feeding on ivermectin-treated blood, mosquitoes survived an average of 7 days. Ivermectin exhibited a significantly stronger and faster mosquito-killing effect when applied to treated surfaces, eliminating mosquitoes within 24–48 h.”
Researchers also found that contact-exposure to ivermectin has the potential to block the development of Plasmodium parasites, which are responsible for malaria, in infected mosquitoes. They suggested that ivermectin impairs the sexual development of the parasite inside the mosquitoes’ midgut.
“The results of this study highlight the potential of ivermectin as a promising synergist to traditional insecticide-based vector control strategies. This transmission-blocking activity adds an important dimension to ivermectin’s potential as a malaria control tool,” the study said.
The study was funded by the Indian Council of Medical Research—National Institute of Malaria Research, the University Grants Commission, and the Council of Scientific and Industrial Research. The authors declared no competing interests in the study.
Among previous studies, some have questioned the efficacy of ivermectin to treat malaria in humans, while others have confirmed its positive impact,
In a June 2021 study published in the Cochrane Library, researchers detailed the results of a test conducted in eight villages in the West African nation of Burkina Faso, where people received doses of ivermectin.
Researchers concluded that the study did not demonstrate ivermectin’s effect on the cumulative incidence of malaria among children during the 18-week study period.
“We are uncertain whether community administration of ivermectin has an effect on malaria transmission,” they wrote.
Another study, published in The New England Journal of Medicine on July 23, found ivermectin to be beneficial for malaria treatment. It analyzed children, aged 5 to 15, living in a Kenyan county where malaria was endemic and the use of insecticide-treated bed nets was high.
Administering a dose of ivermectin once a month for three straight months was found to have led to a 26 percent lower incidence of malaria infection compared to a control drug.
Malaria Worldwide
According to a December 2024 post by the World Health Organization (WHO), globally in 2023, there were an estimated 263 million malaria cases and 597,000 malaria deaths in 83 countries.
“The WHO African Region carries a disproportionately high share of the global malaria burden. In 2023, the WHO African Region was home to 94 percent of malaria cases (246 million) and 95 percent (569 000) of malaria deaths,” it said.
In the United States, malaria is not endemic, meaning it does not regularly occur or spread in the country. Approximately 2,000 malaria cases are reported annually in the country, according to the Centers for Disease Control and Prevention.
Ivermectin During Pandemic
During the COVID-19 pandemic, some researchers promoted ivermectin as a potential treatment for the illness, despite federal officials not approving it.
In an August 2021 X post, the Food and Drug Administration asked people to stop using ivermectin. “You are not a horse. You are not a cow. Seriously, y’all. Stop it,” it said, referring to the fact that ivermectin is commonly used as a veterinary medicine.
A June 2021 study found ivermectin to be associated with “large reductions” in COVID-19 deaths.
According to researchers, the risk of death among people hospitalized with COVID-19 who were treated with ivermectin was 2.3 percent compared to 7.8 percent among those who did not receive the drug.
Another 2022 study examining ivermectin use in COVID-19 patients found that it resulted in decreased mortality compared to remdesivir, the medication federally authorized by the FDA for emergency use to treat COVID-19.
In recent years, some states in the United States have moved to allow ivermectin to be sold as an over-the-counter medication. In 2022, Tennessee permitted the sale of ivermectin without a prescription requirement. Arkansas and Idaho followed suit this year.
Potential side effects of ivermectin include vomiting, nausea, constipation, loss of appetite, chest discomfort, and weakness. Some of the serious consequences include coma, hives, peeling skin, and confusion.
As of now, the FDA hasn’t approved ivermectin as a treatment for COVID-19.
“The FDA has not authorized or approved ivermectin for the treatment or prevention of COVID-19 in people or animals. The FDA has not determined that ivermectin is safe or effective for these indications (uses),” the agency stated on its website.
Safeguarding Your American Dream: Discover the Power of America First Healthcare
In today’s economy, healthcare costs remain one of the biggest threats to financial stability and family security. Americans work hard to build a better life, yet rising medical expenses can quickly erode savings, force tough trade-offs, and even push families toward debt or bankruptcy. Medical bills continue to rank as the leading cause of personal bankruptcy in the United States, with millions facing underinsurance or unexpected out-of-pocket burdens that no one plans for. Many turn to government-run marketplace plans under the Affordable Care Act, hoping for relief, only to discover that what appears affordable on paper often delivers higher long-term costs, limited real protection, and coverage that may not align with personal values or family needs.
America First Healthcare stands out as a private insurance agency dedicated to helping conservatives and families secure better coverage and better rates through customized, values-aligned options. By conducting free insurance reviews, the agency uncovers hidden gaps in existing policies and connects clients with private alternatives that emphasize personal responsibility, small-government principles, and genuine affordability—often delivering up to 20% savings while providing stronger protection for the American Dream.
The allure of marketplace plans is easy to understand: open enrollment periods, premium tax credits for many households, and the promise of “comprehensive” benefits mandated by law. Yet recent data reveals a different reality, especially after the expiration of enhanced premium subsidies at the end of 2025. Enrollment for 2026 dropped by more than one million people compared to the prior year, with many shifting to lower-tier bronze plans to keep monthly premiums manageable.
These plans feature significantly higher deductibles—averaging around $7,500 nationally—and greater cost-sharing requirements. Families who once paid modest amounts after subsidies now face average premium increases of $65 or more per month, even as they accept plans that leave them responsible for thousands in upfront costs before meaningful coverage kicks in.
High deductibles create a dangerous barrier to care. Studies show that people in such plans are less likely to seek timely treatment for chronic conditions, attend preventive screenings, or fill necessary prescriptions. A seemingly minor illness or injury can balloon into major expenses when patients delay care until problems worsen. For a family of four, a single hospitalization, cancer diagnosis, or unexpected surgery can easily exceed the deductible, triggering coinsurance and out-of-pocket maximums that still leave substantial bills. One recent analysis noted that some proposed changes could push family deductibles toward $31,000 in future years, further exposing households to financial risk.
Beyond the numbers, marketplace plans often carry structural limitations. Coverage for certain critical services may include waiting periods or narrower networks that restrict access to preferred doctors and specialists. Preventive care is required to be covered without cost-sharing, but everything else—lab work, imaging, specialist visits, or ongoing treatment—typically waits until the deductible is met. This reactive model contrasts sharply with the proactive, holistic approach many families prefer, especially those focused on wellness, early intervention, and maintaining health to enjoy life rather than merely reacting to illness.
Values alignment represents another growing concern. Government-influenced plans operate within a framework shaped by federal mandates and political priorities that may not reflect conservative principles of limited government, personal freedom, and ethical stewardship. Families who want to direct their healthcare dollars toward providers and benefits that honor traditional values sometimes find marketplace options feel misaligned, forcing a compromise between affordability and conviction.
Private alternatives, by contrast, offer year-round flexibility without the restrictions of open enrollment windows. Independent agents can shop across a wider range of carriers to design plans tailored to specific family needs—whether that means lower deductibles for frequent medical users, broader provider networks, or add-ons that support wellness and preventive services from day one. Clients frequently report more stable premiums that do not automatically escalate each year, along with genuine cost savings once the full picture of deductibles, copays, and coverage depth is considered.
Take the experience of real families who made the switch. Amanda C. shared that her new plan felt “way better” than what she had through the marketplace. Johnny Y. noted his previous coverage kept increasing annually until he found a more stable private option. Sofia S. expressed delight with her plan and began recommending it to others. These stories echo a common theme: when families move beyond one-size-fits-all government marketplaces, they often discover customized protection that better safeguards both health and finances.
Founder Jordan Sarmiento’s own journey underscores the stakes. In 2021, a six-day hospitalization generated a $95,000 bill. Under a well-structured private “Conservative Care Coverage” plan, his out-of-pocket responsibility would have been just $500. That stark difference illustrates how thoughtful planning and private options can prevent a medical event from becoming a financial catastrophe.
Practical steps exist for anyone questioning their current coverage. Start with a no-obligation review of your existing policy to identify gaps—high deductibles, limited critical-care benefits, or escalating premiums. Compare total projected costs (premiums plus potential out-of-pocket expenses) rather than monthly premiums alone. Consider family health history, anticipated needs, and lifestyle priorities. Private agencies can present side-by-side options that include stronger wellness incentives, broader access, and plans built on shared values of self-reliance and freedom.
In an era when healthcare inflation continues to outpace general cost-of-living increases, relying solely on marketplace solutions carries growing risk. Families who proactively explore private alternatives frequently achieve meaningful savings while gaining peace of mind that their coverage truly works when needed most.
America First Healthcare makes this exploration straightforward through its free review process. Families and individuals receive personalized guidance to close coverage holes, reduce unnecessary expenses, and secure plans that align with conservative principles—protecting wallets, health, and the American Dream without government overreach. Many who complete a review discover they can enjoy better benefits for less, often saving up to 20% while gaining the customization and stability that marketplace plans struggle to deliver.
Ultimately, protecting your family’s future requires looking beyond the marketing of “affordable” government options. By understanding the long-term costs hidden in high deductibles, shifting coverage tiers, and values mismatches, Americans can make empowered choices. Private, values-driven insurance offers a smarter path—one that rewards diligence, supports wellness, and delivers real security. For those ready to move beyond the limitations of traditional marketplace plans, a simple review can reveal options designed to serve families, not bureaucracies. The American Dream thrives when individuals and families retain control over their healthcare decisions, and thoughtful private coverage plays a vital role in making that possible.